Introduction
Gene therapy is a novel treatment approach that may potentially enhance the treatment of genetic disease. Improvements in the gene transfer vector used in therapeutic trials have resulted in substantial clinical success in patients with serious genetic conditions, such as immunodeficiency syndromes and blindness. In recent years, more and more epigenetic and genetic observations in somatic cells have supported that cancer also is a genetic disease. Cancer cells share certain key features: evasion of apoptosis, insensitivity to antigrowth signals, invasion, metastasis and enhancement of angiogenesis. These features are targets for gene therapy treatments. To identify an essential target and treatment with gene transfer approach will provide a new therapeutic option for cancer patients.
14-3-3 proteins were isolated from bovine brain, and purified in the purification scheme with diethylaminoethyl-cellulose (DEAE-cellulose) column chromatography followed by starch gel electrophoresis. It is a family of highly conserved dimeric proteins that are ubiquitously expressed in eukaryotic organisms and highly abundant in the brain. 1 14-3-3 proteins have an important role in a wide range of biologic processes through a variety of regulatory mechanisms by binding to phosphorylatedserine/threonine motifs in diverse partners, such as signal transduction, cell-cycle control, vesicular transport, DNA replication, DNA repair, apoptosis, cellular metabolism, cytoskeleton organization and malignant transformation. [2] [3] [4] [5] [6] Meanwhile, a few proteins associate with 14-3-3 proteins independent of serine/threonine sequence motifs. 14-3-3 proteins can interact with 4100 key proteins in cancer. Furthermore, preliminary work indicated that global inhibition or downregulation of 14-3-3 protein suppressed tumor growth. Therefore, 14-3-3 proteins may affect multiple signal pathways through phosphorylationdependent and/or independent ways in cancer.
14-3-3 proteins have elevated expression in cancer and cell lines derived from tumors. [7] [8] [9] [10] Previous studies showed that 14-3-3 might be a potential oncogene. 11 Together, these findings enhance our perceptions of 14-3-3 as a potential oncogene. In mammals, the 14-3-3 protein family is composed of seven subtypes, called as b, g, e, z, y, Z and s. 12 It is a puzzle which subtype mainly contributes to tumor genesis? Recent studies have shown that 14-3-3zeta interacts with many key cellular proteins involved in the tumor development and progression. 13 The importance of 14-3-3zeta in the formation and progression of cancer has been emphasized within several tumor types. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In this review, we will investigate the role of 14-3-3zeta in cancer and suggest a new target in anticancer therapy.
Why is 14-3-3zeta an attractive target for anticancer therapy?
14-3-3zeta expression in normal and tumor tissues Cytoplasmic expression of 14-3-3zeta protein is commonly observed in many tissues, but some tissues also show nuclear localization (Table 1) . Sometimes, cytoplasmic and nuclear expression is observed even in the same tissue. 19 14-3-3zeta-positive expression occurs in the lung cancer, [25] [26] [27] [28] liver cancer, 21 uterus, breast carcinoma, 14 stomach cancer, 29 head and neck squamous cell carcinoma 15 and so on. In addition, 14-3-3zeta protein expression is elevated in the breast cancer, 14 36 which shows 14-3-3zeta overexpression also occurred in cervical, ovarian, skin, pancreatic, prostate and urothelial tumors. 14-3-3zeta protein also is secreted by tumor-associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. 37 Overexpression of 14-3-3zeta in hyperplasia, dysplasia and carcinoma indicates that alteration in its expression occurs in early stages and is associated with tumorigenesis. Together, these data suggest that 14-3-3zeta-positive expression has an important role in the tumor genesis and progression in multiple types of cancer.
In the progenitor cells, 14-3-3zeta is initially localized in the cytoplasm. When differentiation of progenitors is induced, 14-3-3zeta is translocated into the nucleus.
38 The 14-3-3zeta and Hsp60 protein are colocalized chiefly in the mitochondria of human neuronal progenitor cells in culture, and are co-expressed most prominently in neurons and reactive astrocytes in the human brain. 39 But there are few reports on the expression and functions of 14-3-3zeta in cancer stem cells. The demonstration of 14-3-3zeta functions in cancer stem cell may provide a new field for cancer treatment.
Potential pathways of 14-3-3zeta involvements in tumor genesis and progression The primary mechanism for 14-3-3zeta interaction with target protein is serine/threonine phosphorylation of the targeting protein dependent on two prototype 14-3-3zeta-binding motifs, RSXpSXP and RXY/FXXpSXP (pS represents phosphoserin and X any amino acid). It is very important for 14-3-3zeta involving in the multiple cell processes. However, we will emphasize the signal pathways and molecule interacting with 14-3-3zeta in cancer.
Oncogene
Gene amplification is one of the common molecular mechanisms for oncogene activation in cancers. Gene gains of 14-3-3zeta on chromosome 8q22.3 are found in 30-40% head and neck squamous cell carcinoma cases. 15 Frequent high-level gains of 14-3-3zeta copy number, high messenger RNA and protein level are also observed in these patients' tumor tissues. Furthermore, 14-3-3zeta RNAi significantly suppresses the growth rate of head and neck squamous cell carcinoma cell lines, and overexpression of 14-3-3zeta in HaCaT-immortalized human skin keratinocytes promotes overgrowth, as well as morphological changes. Reduced 14-3-3zeta levels increase the G1/G0-phase proportion, decrease the S-phase proportion and the rate of DNA synthesis. A functional genomic approach integrating microarray and proteomic analyses has identified 14-3-3zeta as a putative oncogene whose activation is common and promoted by its genomic amplification in lung adenocarcinomas. 40 Downregulation of 14-3-3zeta sensitizes cells to stress-induced apoptosis and c-Jun N-terminal kinase/p38 signaling, and enforces cell-cell contacts and expression of adhesion proteins. Apparently, the zeta isoform restrains both cell adhesion and the cellular propensity for apoptosis, two activities that are also restrained during carcinogenesis. 41 Moreover, 14-3-3zeta shows a constant upregulation of the transcripts in a cottontail rabbit papillomavirus squamous carcinoma model employing New Zealand 14-3-3zeta in cancer X Yang et al White rabbits. 42 A web-based meta-analysis (Oncomine) reveals 14-3-3zeta overexpression in various types of carcinomas, 41 suggesting its oncogene property. Based on these evidences, we suggest that 14-3-3zeta is a candidate proto-oncogene and deserves further investigation into its role in carcinogenesis.
Cell survival and apoptosis
Cell fate is decided by integrating a variety of apoptotic and survival signals. Therefore, there is likely to be a common mechanism that integrates multiple signals adjudicating between the alternatives. The involvements of 14-3-3zeta in cell survival and apoptotic signals have been demonstrated in several cancer types. Upregulated 14-3-3zeta expression enhances anchorage-independent growth and suppresses stress-induced apoptosis, whereas downregulation of 14-3-3zeta inhibits anchorage-independent growth and sensitizes cells to stress-induced apoptosis via the mitochondrial apoptotic pathway. Transient blockade of 14-3-3zeta expression by small interfering RNA (siRNA) in cancer cells effectively reduces the onset and growth of tumor xenografts in vivo. [13] [14] [15] 20, 21, 27, 34, 43 In the cancer cells, 14-3-3zeta is commonly associated with some pro-apoptotic proteins upon phosphorylation with survival-mediating kinases, such as Akt. Phosphorylation of 14-3-3zeta by c-Jun N-terminal kinase releases the proapoptotic proteins Bad and FOXO3a from 14-3-3zeta, and antagonizes the effects of Akt signaling. 21, [44] [45] [46] As a result of dissociation, Bad is dephosphorylated and translocates to the mitochondria, where it associates with Bcl-2/Bcl-x(L), promoting apoptosis via the mitochondrial apoptotic pathway, including cytochrome c release and procaspase-9 cleavage.
14 Meanwhile, downregulation of 14-3-3zeta enhances anoikis mediated in part by downregulated Bcl-2 protein and upregulated BH3-only proteins, Bad, Bax and Bim, coupled with decreased Mcl-1, resulting in the subsequent activation of Bax, caspase-9 and caspase-3.
27,43
These data not only reveal a critical role of 14-3-3zeta in apoptosis suppression in multiple cancers, but also identifies and validates 14-3-3zeta as a potential molecular target for anticancer therapeutic development.
Cell cycle
Reduced 14-3-3zeta levels increase the G1/G0-phase proportion, decrease the S-phase proportion and the rate of DNA synthesis in cells. 15, 43 However, how does 14-3-3zeta protein involve in the cell cycle? There are some cues to be inferred in some reports. 14-3-3zeta protein binds, in a phosphorylation-dependent fashion, to several important cytoplasmic and nuclear proteins, including cyclin D1, CDC25 and Raf-1, at least in part, to sequester proteins in particular states or subcellular compartments. [47] [48] [49] Cyclin D1 is found to form complex with chaperon 14-3-3zeta in unstressed cells but mutation of 14-3-3zeta significantly impairs 14-3-3zeta binding to cyclin D1. As well known, cyclin D1 is involved in cell-cycle arrest in DNA-damage response.
47 CDC25 dual-specificity phosphatases are essential regulators that activate cyclin-dependent kinases at critical stages of the cell cycle. In human cells, CDC25A and C are involved in the control of G1/S and G2/M phase, respectively, whereas CDC25B is proposed to act both in S and G2/M phase. The interaction between CDC25 phosphatases and 14-3-3zeta has been obtained in vitro and in vivo in several organisms. 48 
DNA replication
The 14-3-3zeta protein has been identified as an origin of DNA-replication-binding protein and involved in DNA replication. Pure recombinant 14-3-3zeta tagged with maltose-binding protein (r14-3-3zeta-MBP) for binding to cruciform DNA. The r14-3-3zeta-MBP has cruciform binding activity. Furthermore, addition of r14-3-3zeta-MBP to HeLa cell extracts used in a mammalian in vitro replication system increased the level of DNA replication by B3.5-fold. The data suggest that 14-3-3zeta has CBP activity and the upregulation of this activity leads to an increase in DNA replication. 50 
Cell skeleton, invasion and metastasis
Tumor cell invasion and metastasis contains multiple steps that require changes in cell cytoskeleton, cell adhesion and extracellular matrix to which they adhere. Recent studies have suggested that the migration and invasion of tumor cells is controlled, in part, dependent on a6b4 integrin/ Rac1 signaling. 51, 52 This pathway signals focus to the major regulator of cellular actin dynamics, cofilin, 53 its activity dependent on phosphorylation/dephosphorylation at Ser3, modulating cytoskeletal organization and cell migration. 14-3-3zeta protein involves in the regulation of cellular actin structures through the maintenance of phosphorylated-cofilin levels. 54 Moreover, 14-3-3zeta forms the regulatory complex with the Slingshot-1L (SSH-1L), a selective cofilin-regulatory phosphatase. The oxidation of 14-3-3zeta activates the SSH-1L-cofilin pathway to increase membrane ruffling and cell motility, and regulates cytoskeletal organization and cell migration. 55, 56 The ADAM family contains disintegrin-like and metalloproteinase-like domains, which potentially have cell adhesion and protease activities. Exogenous 14-3-3zeta greatly enhanced the adhesion and spreading of cells overexpressing ADAM22. The enhanced ability gained by exogenous ADAM22 and 14-3-3zeta is much more than the summation of enhancement effect of ADAM22 and 14-3-3zeta individually. 57, 58 The interaction between 14-3-3zeta and ADAM22 affects cell adhesion and spreading. The overexpression of exogenous ADAM22 with 14-3-3zeta-binding motifs in HEK293 cells could significantly enhance cell adhesion and spreading, compared with the truncated ADAM22 lack of 14-3-3-binding motifs. 57 14-3-3zeta in cancer X Yang et al
14-3-3zeta and common tumor-associated molecules
ErbB2 is a metastasis-promoting oncoprotein, overexpressed in more noninvasive ductal carcinoma in situ than in invasive/metastatic breast cancers. The co-overexpression of 14-3-3zeta in ErbB2-overexpressing ductal carcinoma in situ confers a higher risk of progression to invasive breast cancer. ErbB2 and 14-3-3zeta overexpression, respectively, increases cell migration and decreases cell adhesion. 14-3-3zeta overexpression reduces cell adhesion by activating the TGF-beta/Smads pathway that led to ZFHX1B/SIP-1 upregulation, E-cadherin loss and epithelial-mesenchymal transition. Importantly, patients whose breast tumors overexpress both ErbB2 and 14-3-3zeta have higher rates of metastatic recurrence and death than those whose tumors overexpress only one. 24 14-3-3zeta associates with beta-catenin complex and facilitates activation of beta-catenin by PTEN/Akt in intestine stem cells. 59 In addition, 14-3-3 zeta overexpression associated with downregulation of p53 increases the risk of tumorigenesis. 60, 61 An association of 14-3-3zeta with the epidermal growth factor receptor (EGFR) is rapidly induced by EGF. The EGFR and 14-3-3zeta are colocated along the plasma membrane. This finding indicates a role for 14-3-3 proteins in EGF receptor signaling or regulation. 62 
14-3-3zeta and tumor chemotherapy
A promising anticancer agent, 14-3-3zeta is noted for its ability to induce apoptosis specifically in malignant cells. However, a major obstacle for successful cancer treatment by these and other chemotherapeutic agents is the intrinsic or acquired resistance to drug treatment. 14-3-3zeta has an important role in some common chemotherapy-resistant cancer. 14-3-3zeta is the differently expressed protein in some chemorefractory tumors, including diffuse large B-cell lymphoma and prostate cancer. 34, 63 Overexpression of 14-3-3zeta attenuates chemotherapy-induced cell death, whereas RNAi-based 14-3-3zeta knockdown enhances tumor cell sensitivity to the chemotherapeutic agent induction in multiple myeloma, 30 diffuse large B-cell lymphoma, 63 acute promyelocytic leukemia, 64 lung cancer, 40, 65 prostate cancer, 34 hepatoma 21 and breast cancer. 14 These observations implicate 14-3-3zeta as potential molecular target for drug intervention, and thus improve antitumor activity of chemotherapeutic agents.
14-3-3zeta and tumor patient prognosis
The upregulated expression of 14-3-3zeta is associated with histological grades, lymph node metastasis and poor clinical outcome in some cancer types. Furthermore, 14-3-3zeta might be used as prognostic biomarkers for these cancers. 13, 66 Fan et al. 40 analyzed 57 patients with nonsmall-cell lung cancer with various histological types and clinical stages. The increased 14-3-3zeta expression was positively correlated with a more advanced pathologic stage and grade of non-small-cell lung cancers, and was associated with overall and cancer-specific survival rates of the patients at 5 years after surgery. By performing multivariate analysis (age, sex, histological type and smoking status) using the Cox model, the overexpression of 14-3-3zeta was the only independent predictor for disease-free and cancer-specific survival among the clinical and histological parameters tested. Similarly, Neal et al.
14 analyzed 121 patients with invasive breast carcinoma with a median follow-up time of 67 months. Strong 14-3-3zeta staining was also significantly associated with reduced overall survival and was determined to be an independent prognostic factor for disease-free survival in multivariate analysis. Matta et al. 16 also analyzed 51 patients with head and neck/oral squamous cell carcinoma. They found that the median disease-free survival (13 months) with overexpression of both 14-3-3zeta and stratifin proteins was significantly shorter than that (38 months) for patients who did not show overexpression of these proteins. We analyzed 47 patients with glioblastoma and found that 14-3-3zeta-positive expression was associated with a significant decrease in 2-year overall survival rates and survival time, and significant increase in cancer recurrence interval. 67 All these data support 14-3-3zeta as a potential prognosis factor in cancer.
Strategy for further consideration in the use of 14-3-3zeta as an anticancer target 14-3-3zeta overexpression associated with apoptosis resistance, cancer recurrence and chemoresistance, the inhibition of 14-3-3zeta function will contribute to developing a new strategy for cancer treatment and improving current therapeutic effects. Now, many studies incorporate these novel approaches in combination with standard of care therapies (for example, chemotherapy, as to previous descriptions). At this point, gene therapy for cancer remains experimental and limited. Presently, only gene therapy (mainly RNAi for cancer therapy), antisense and peptide inhibitors are used for targeting 14-3-3zeta under experimental conditions.
RNAi
Gene therapy is the modification of genetic makeup of cells for therapeutic purpose, including gene deletion, downregulation, replacement, expressing exogenous gene for gene deficiency diseases, and so on. Because of the oncogene property of 14-3-3zeta, RNAi is the main gene transfer approach for cancer treatment.
RNAi is first discovered in the nematode Caenorhabditis elegans, 68 and is conserved in many organisms, including mammals. Recently, it has been developed as a 14-3-3zeta in cancer X Yang et al viable and more effective alternative to antisense-and ribozyme-based techniques for gene silencing, offering great potential for cancer therapeutics. 69 One advantage of RNAi in therapy is that the RNAi can specifically downregulate the expression of targeting gene and maintain the function for a few days in some cell types. 70 14-3-3zeta knockdown by siRNA sensitizes cells to stressinduced apoptosis and effectively reduces the onset and growth of tumor in multiple cancer types. 13, 14, 21, 40, 63, 65, 71 However, the clinical application of siRNA put this approach into a dilemma for therapy targeting 14-3-3zeta. The convection-enhanced delivery of siRNA (or shorthairpin RNA, adenovirus and so on) provides a new technique to neuro-system cancer treatment. 72 Peptide inhibitors: R18/difopein R18 is a potent inhibitor of 14-3-3 interaction, nonselectively binding all 14-3-3 isoforms with high affinity. 73 To facilitate delivery of R18 into cells and enhance its efficacy, the difopein (dimeric 14-3-3 peptide inhibitor) plasmid containing two R18 peptides is constructed. 74 This plasmid induces cell apoptosis and enhances sensitivity to the antineoplastic agent through disrupting 14-3-3/ligand interaction in COS-7 cells (fibroblast), A549 cells (lung cancer), DU145 cells (prostate cancer), HeLa cells (cervical carcinoma), U251 and U87 (glioma) and leukemia cells. 6, 43, 75 Recently, FOBISIN101, a new small molecule modulator of 14-3-3, was found to effectively block the binding of 14-3-3 with Raf-1 and praline-rich AKT substrate. 76 Previous study has showed that overexpression of 14-3-3zeta in cancer cells activates PI3K/ AKT signal. 77 FOBISIN101 could be developed as a new inhibitor of 14-3-3zeta, and serve as a novel agent for cancer intervention. Current 14-3-3zeta-targeting approaches are limited to knockdown experiments and peptide inhibitors, but discovering 14-3-3zeta-interacting molecules and developing a specific antibody or inhibitor that recognizes and blocks the functions or activation of 14-3-3zeta may indicate a new field for 14-3-3zeta-targeting therapy in clinical application. Combination tumor suppressor or other forms of gene therapy with inhibition of 14-3-3zeta may led to synergistic effects and be appealing. It is also a new field for the next study.
Conclusions
Recent studies have showed that 14-3-3zeta overexpression is significantly associated with disease recurrence and resistance to chemotherapeutic agents in cancer patients. Overexpression of 14-3-3zeta has been associated with anchorage-independent growth and a survival advantage in multiple cancers. In contrast, knockdown of 14-3-3zeta reduces tumor growth and sensitizes cells to chemotherapeutic agents. 14-3-3zeta has been identified as a clinically relevant prognostic marker for cancer patients, so this finding provides an opportunity to identify patients for more aggressive therapy. These findings not only reveal a critical role of 14-3-3zeta in tumor genesis and progression, but also identify and validate 14-3-3zeta as a potential molecular target for anticancer therapeutic development.
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